HLA-DR alpha 2 mediates negative signalling via binding to Tirc7 leading to anti-inflammatory and apoptotic effects in lymphocytes in vitro and in vivo

PLoS ONE

Volumn 3, Issue 2, 2008, Pages

  Bulwin, Grit Carsta ^a   Wälter, Stephanie ^a   Schlawinsky, Mirko ^a   Heinemann, Thomas ^b   Schulze, Anke ^a   Höhne, Wolfgang ^c   Krause, Gerd ^d   Kalka Moll, Wiltrud ^e   Fraser, Patricia ^f   Volk, Hans Dieter ^g   Löhler, Jürgen ^h   Milford, Edgar L ^f   Utku, Nalân ^a,g  

^a CellAct Pharma GmbH   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HUMBOLDT UNIVERSITY   (Germany)

^h LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; HLA DR ALPHA 2 ANTIGEN; HLA DR ANTIGEN; MEMBRANE PROTEIN; PROTEIN KINASE ZAP 70; PROTEIN TIRC7; STAT4 PROTEIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; TCIRG1 PROTEIN, HUMAN;

ALPHA CHAIN; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE; METABOLISM; SIGNAL TRANSDUCTION;

APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; HLA-DR ANTIGENS; HUMANS; INFLAMMATION; LYMPHOCYTES; SIGNAL TRANSDUCTION; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 45349095849     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001576     Document Type: Article

References (27)

1. Utku N, Heinemann T, Tullius SG, Bulwin G-C, Beinke S, et al. (1998) Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity 9: 509-518.
2. Kumamoto Y, Tomschegg A, Bennai-Sanfourche F, Boerner A, Kaser A, et al. (2004) Monoclonal antibody specific for TIRC7 induces donor-specific anergy and prevents rejection of cardiac allografts in mice. Am J Transplant 4: 505-514.
3. Utku N, Heinemann T, Winter M, Bulwin G-C, Schlawinsky M, et al. (2006) Antibody targeting of TIRC7 results in significant therapeutic effects on in collagen-induced arthritis in mice. Clin Exp Immunol 144: 142-151.
4. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH (2003) Molecular mechanisms regulating TH1 immune responses. Annu Rev Immunol 21: 713-58.
5. Wang LH, Kirken RA, Erwin RA, Yu CR, Farrar WL (1999) JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J Immunol 162: 3897-3904.
6. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, et al. (2003) BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4: 670-679.
7. Zhang Q, Raghunath PN, Vonderheid E, Ødum N, Wasik MA (2000) Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 157: 1137-1146.
8. Hsu H-C, Shultz LD, Su X, Shi J, Yang P-A, et al (2001) Mutation of the hematopoietic cell phosphatase (Hcph) gene is associated with resistance to γ-irradiation-induced apoptosis in Src homology protein tyrosine phosphatase (SHP)-1-deficient "motheaten" mutant mice. J Immunol 166: 772-780.
9. + anaplastic large-cell lymphoma. Blood 108: 2796-2803.
10. Brockdorff J, Williams S, Couture C, Mustelin T (1999) Dephosphorylation of ZAP-70 and inhibition of T cell activation by activated SHP1. Eur J Immunol 29: 2539-2550.
11. Kovacs B, Liossis S-NC, Gist ID, Tsokos GC (1999) Crosslinking of Fas/ CD95 suppresses the CD3-mediated signaling events in Jurkat T cells by inhibiting the association of the T-cell receptor ζ chain with src-protein tyrosine kinases and ZAP70. Apoptosis 4: 327-334.
12. Rathmell JC, Thompson CB (2002) Pathways of apoptosis in lymphocyte development, homeostasis, and disease. Cell 109: 97-107.
13. Riedl SJ, Shi Y (2004) Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5: 897-907.
14. Hipfner DR, Cohen SM (2004) Connecting proliferation and apoptosis in development and disease. Nat Rev Mol Cell Biol 5: 805-815.
15. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML (1999) The immunological synapse: A molecular machine controlling T cell activation. Science 285: 221-227.
16. Bulwin G-C, Heinemann T, Bugge V, Winter M, Lohan A, et al. (2006) TIRC7 inhibits T cell proliferation by modulation of CTLA-4 empression. J Immunol 15: 6833-6841.
17. Dinges M, Schlievert P (2001) Role of T cells and gamma interferon during induction of hypersensitivity to lipopolysaccharide by toxic shock syndrome toxin 1 in mice. Infect Immun 69: 1256-1264.
18. Frederick P, Heinzel RM, Rerko FA, Hujer AM (1996) IFN-γ-independent production of IL-12 during murine endotoxemia. J Immunol 157: 4521-4528.
19. Paul WE (1993) Fundamental Immunology, 3rd edition.
20. Marsh SGE, Parham P, Barber LD (2000) The HLA Facts Book.
21. Parham P (1999) Virtual reality in the MHC. Emmunol Rev 167: 5-15.
22. Herman A, Kappler JW, Marrack P, Pullen AM (1991) Superantigens: mechanism of T-cell stimulation and role in inumme responses. Annu Rev Immunol 9: 745-772.
23. Irwin MJ, Hudson KR, Ames KT, Fraser JD, Gascoigne NR (1993) T-cell receptor beta chain binding to enterotoxin superantigen. Immunol Rev 131: 61-78.
24. Li H, Liera A, Malchiodi EL, Mariuzza RA (1999) The structural basis of T cell activation by superantigens. Annu Rev Emmunol 17: 435-466.
25. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, et al. (1994) Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 368: 711-718.
26. Karp DR, Teletski CL, Scholl P, Geha R, Long EO (1990) The 1 domain of the HLA-DR molecule is essential for affinity binding of the toxic shock syndrome toxin-1. Nature 346: 474-476.
27. Kim J, Urban RG, Strominger JL, Wiley DC (1994) Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. Science 266: 1870-1874.